Beranda › Kanker Kandung Kemih › Massachusetts › Boston
Uji klinis Kanker Kandung Kemih di Boston, MA
26 studi untuk Kanker Kandung Kemih mencari peserta di lokasi sekitar Boston (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Menerima pesertaFase 1
- Massachusetts General Hospital, Boston
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Menerima pesertaFase 3
- Brigham and Women's Hospital, Boston
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Menerima pesertaFase 2
- Massachusetts General Hospital Cancer Center, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Menerima pesertaFase 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Menerima pesertaFase 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Menerima pesertaFase 2
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Patient-Centered Surgical Prehabilitation
Menerima pesertaSukarelawan sehat diterima
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Menerima pesertaFase 3
- Dana Farber Cancer Institute ( Site 0783), Boston
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Menerima pesertaFase 3
- Massachusetts General Hospital, Boston
Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy
Menerima peserta
- Dana Farber Cancer Institute, Boston
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Menerima pesertaFase 1
- Dana-Farber Cancer Institute, Boston
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Menerima pesertaFase 2
- Brigham and Women's Hospital, Boston
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Menerima pesertaFase 2
- Brigham and Women's Hospital, Boston
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Menerima pesertaFase 1
- Massachusetts General Hospital, Boston
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Menerima pesertaFase 3
- Massachusetts General Hospital Cancer Center, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Massachusetts General Hospital Cancer Center, Boston
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Menerima pesertaFase 1/2
- Brigham and Women's Hospital, Boston
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Menerima pesertaFase 2/3
- Local Institution - 0195, Boston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Menerima pesertaFase 2
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Menerima pesertaFase 3
- Research Site, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Menerima pesertaFase 1
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- dan 2 lainnya
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
Menerima pesertaStudi observasional
- Dana-Farber Cancer Institute, Boston
CONFIRM: Magnetic Resonance Guided Radiation Therapy
Menerima peserta
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Sacituzumab Govitecan Plus EV in Metastatic UC
Menerima pesertaFase 1/2
- Dana Farber Cancer Institute, Boston
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
Menerima peserta
- Harvard School of Medicine/Massachusetts General Hospital (MGH), Boston
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
Menerima pesertaFase 3
- Brigham and Women's Hospital, Boston
Uji klinis Kanker Kandung Kemih di kota lain
- New York City, NY35 studi
- Nashville, TN31 studi
- Houston, TX31 studi
- Dallas, TX27 studi
- Washington, DC26 studi
- Los Angeles, CA24 studi
- Baltimore, MD24 studi
- St. Louis, MO22 studi
- Philadelphia, PA21 studi
- Seattle, WA21 studi
- Edison, NJ21 studi
- Chicago, IL21 studi
Studi lain di Boston
- Kanker Payudara111 studi
- Kanker Paru Non-Sel Kecil90 studi
- Kanker (semua jenis)86 studi
- Kanker Kolorektal63 studi
- Kanker Metastatik63 studi
- Kanker Paru62 studi
- Kanker Ovarium61 studi
- Kanker Prostat59 studi
- Depresi52 studi
- Kanker Endometrium50 studi
- Gagal Jantung44 studi
- Leukemia Mieloid Akut44 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.